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ABSTRACT  37 
Context: While both overt hyper- and hypothyroidism are known to lead to cognitive impairment, data on 38 
the association between subclinical thyroid dysfunction and cognitive function are conflicting.   39 
Objective: To determine the risk of dementia and cognitive decline associated with subclinical thyroid 40 
dysfunction among prospective cohort studies. 41 
Data Sources: Search in MEDLINE and EMBASE (inception until November 2014) and reference lists of 42 
key articles without language restrictions. 43 
Study Selection: Two physicians identified prospective cohorts that assessed thyroid function at baseline 44 
and cognitive outcomes (dementia; Mini-Mental State Examination, MMSE). 45 
Data Extraction: Data were extracted by one reviewer following standardized protocols and verified by a 46 
second reviewer. Both reviewers independently assessed study quality. The primary outcomes were de-47 
mentia and decline in cognitive function measured by MMSE. We calculated risk ratios and 95% confi-48 
dence intervals using random-effects models. 49 
Data Synthesis: Eleven prospective cohorts followed 16,805 participants during a median follow-up of 50 
44.4 months. Five studies analyzed the risk of dementia in subclinical hyperthyroidism (n=6410), six in 51 
subclinical hypothyroidism (n=7401). Five studies analyzed MMSE decline in subclinical hyperthyroid-52 
ism (n=7895), seven in subclinical hypothyroidism (n=8960). In random-effects models, the pooled ad-53 
justed RR for dementia in subclinical hyperthyroidism was 1.67 (95% confidence interval [CI] 1.04-2.69) 54 
and 1.14 (95%CI 0.84-1.55) in subclinical hypothyroidism versus euthyroidism, both without evidence of 55 
significant heterogeneity (I2=0.0%). Sensitivity analyses pooling only studies with formal outcome adjudi-56 
cation or population-based studies yielded similar results. The pooled mean MMSE decline from baseline 57 
to follow-up (mean 32 months) did not significantly differ between subclinical hyper- or hypothyroidism 58 
versus euthyroidism.  59 
Conclusions: Subclinical hyperthyroidism might be associated with an elevated risk for dementia, while 60 
subclinical hypothyroidism is not, and both conditions are not associated with faster decline in MMSE 61 
over time. Available data are limited, and additional large, high-quality studies are needed.  62 
  63 
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CONTEXT 64 
The prevalence of subclinical hypothyroidism (SHypo) reaches up to 10% in the elderly population, while 65 
subclinical hyperthyroidism (SHyper) has a prevalence of 2.4%, and 4.3% in the population aged ≥80 66 
years.1,2 SHypo is biochemically defined as elevated serum thyroid-stimulating hormone (TSH, thyrotro-67 
pin) levels, but free thyroxin (fT4) levels within laboratory reference ranges3, SHyper is defined as de-68 
creased serum TSH concentrations and normal fT4 and fT3 levels. The subclinical forms of thyroid dys-69 
function have previously been associated with increased risk of heart failure and coronary heart disease.4-6 70 
Furthermore, SHyper may negatively influence bone and mineral metabolism.7  71 
While both overt hyper- and hypothyroidism are known to lead to cognitive impairment and clinical 72 
guidelines recommend screening for thyroid dysfunction among patients with cognitive disorders8, data on 73 
the association between subclinical thyroid dysfunction (SCTD) and cognitive function remained conflict-74 
ing. In the general population, the prevalence of mild cognitive impairment is 3-22%, with a higher preva-75 
lence among adults >70 years (14-18%).9-11 Mild cognitive impairment, a cognitive decline not normal for 76 
age but with essentially preserved functional activities, is believed to be the earliest clinical symptom of 77 
cognitive disorders and may be the stage to intervene with preventive therapies.11,12 The progression rate 78 
from cognitive impairment to dementia in the general population aged > 65 years is around 6-10% per 79 
year.11 SHyper has also been associated with increased risk of dementia, 13 with one retrospective cohort 80 
reporting a hazard ratio of 1.6 (95% confidence interval [CI] 1.2-2.3) for dementia.14 SHypo might also be 81 
associated with alterations in cognitive function,13,15,16 with one case-control study reporting a nearly 4-82 
fold increase in the odds ratio of dementia (OR=3.8, 95%CI 1.6-9.1).17  83 
However, data on the association between SCTD and cognitive function are conflicting.18-20  84 
Two recent meta-analyses yielded discrepant findings for SHypo, one showing a significant risk of cogni-85 
tive alteration (composite endpoint of reduced Mini-Mental State Examination (MMSE), Wechsler 86 
Memory Scale-Revised, total memory quotient and Wechsler Adult Intelligence Scale scores) for SHypo 87 
individuals younger than 75 years with an OR of 1.56 (95%CI 1.07-2.27),21 whereas the other found no 88 
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decline in MMSE in SHypo patients aged ≥60 years (pooled estimate [ES] 0.03, 95%CI −0.001–0.07).22 89 
As both meta-analyses were limited by pooling heterogeneous study designs (prospective and retrospec-90 
tive data), and did neither examine the risk of dementia nor cognitive function associated with SHyper, we 91 
conducted a meta-analysis to determine whether SHyper and SHypo were associated with an increased 92 
risk of dementia or decline in cognitive function in prospective cohorts, the gold standard for observation-93 
al data.  94 
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METHODS 95 
Data sources and Searches 96 
To perform this systematic review, we followed a pre-defined protocol registered on PROSPERO (Rec-97 
ord: CRD42015019819). We conducted a systematic literature search in MEDLINE and EMBASE data-98 
bases from inception until November 2014 searching for articles related to SCTD and cognitive decline 99 
and dementia. The Medical Subject Headings (Mesh) in Ovid MEDLINE included “thyroid disease”, “hy-100 
pothyroidism”, “hyperthyroidism”, “thyroid hormones”, “thyrotropin”, “subclinical hyperthyroidism”, 101 
“subclinical hypothyroidism”, “subclinical dysthyroidism”, “subclinical thyroid”, “cognition”, “demen-102 
tia”, “memory”, “Alzheimer”, “cognitive”, “cohort studies”, “cohort”, “controlled clinical trial”, “epide-103 
miologic methods”, “review”. We applied a cohort filter designed by the British Medical Journal 104 
knowledge information specialists23 but did not use any other filters or restrictions including year limita-105 
tions or language restrictions. A similar strategy with similar terms was used for EMBASE. Additionally, 106 
we searched the bibliographies of included articles, as well as key articles in the field, and contacted sev-107 
eral authors for unpublished subgroup data. 108 
 109 
Study Selection (Figure 1) 110 
Two reviewers (CR, DS) independently screened titles and abstracts of the search results and selected 111 
publications. In a second step, the same two reviewers independently evaluated the full-text publications 112 
of the retrieved studies according to the following pre-specified eligibility criteria: prospective cohort 113 
studies among participants ≥18 years, including a SCTD and a euthyroid control group with thyroid func-114 
tion tests at baseline and assessment of cognitive function during follow-up, with published risk estimates 115 
or sufficient information to calculate them. We excluded studies examining solely participants with overt 116 
thyroid disease. Disagreements were resolved by an independent third author (NR). SHyper was defined 117 
as decreased or undetectable TSH and normal fT4, and SHypo as elevated TSH and normal fT4. Cohort-118 
specific TSH- and fT4-cutoff levels were used to determine thyroid status. For dementia definition, we 119 
accepted all validated assessments of memory and cognitive function, and did not exclude studies that 120 
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reported other scales than MMSE. For our analyses, we also collected information on clinical dementia 121 
(Supplement table 1). Additionally, we gathered data on MMSE results at baseline and follow-up visits 122 
 123 
Data Extraction and Quality Assessment 124 
Standardized data extraction forms were used to collect information from the included cohorts concerning 125 
patient characteristics, thyroid hormone levels, and scales for tests or criteria used to define memory func-126 
tion, dementia or Alzheimer’s disease (AD). Data were extracted by one reviewer (CR) and verified by a 127 
second independent reviewer (DS). Discrepancies were solved by a third author (NR). Two reviewers 128 
(CR, DS) independently assessed study quality using key indicators of cohort study quality24,25: origin of 129 
population (convenience versus population-based, the latter defined as a random sample of the general 130 
population), methods of outcome ascertainment and adjudication (considered as adequate if in each poten-131 
tial case performed by an expert panel blinded regarding the thyroid status and following defined outcome 132 
criteria), completeness of follow-up, assessment of the proportional hazard assumption and adjustment for 133 
confounders.  134 
 135 
Data Synthesis and Statistical Analysis 136 
We expressed the estimates of the association between SCTD (i.e. SHyper or SHypo) and outcomes as 137 
risk ratios (RR) for dementia or as between-group differences in mean changes from baseline for MMSE 138 
scores (MD). Only prospective data were analyzed. A RR>1 indicates a higher risk of an event in SCTD 139 
compared to euthyroids and a MD>0 indicates higher decline of MMSE in SCTD compared to euthyroids. 140 
To account for the different lengths of follow-up time across studies, we standardized MD per 1 year unit. 141 
We used most adjusted estimates provided by the studies as primary analysis. We used an inverse variance 142 
random-effects meta-analysis to pool estimates across studies. Estimates of the association between SCTD 143 
and dementia were pooled on a log scale and latter exponentiated to be reported as RR. To evaluate heter-144 
ogeneity across the studies, we used the Q statistic with a conservative p-value of 0.10.26 Furthermore, we 145 
calculated the I2 statistic, indicating the proportion of variability in estimates of effects across studies that 146 
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is not due to chance alone (<25% low, 25-75% increasing, >75% high heterogeneity between studies).24 147 
We visually evaluated publication bias through funnel plots and, statistically, with the Egger’s test.27,28 To 148 
explore the sources of heterogeneity, we conducted several sensitivity analyses. Due to the small number 149 
of studies in each group, subgroup analysis with interaction tests could not be meaningfully performed. 150 
All P-values were two-sided. All analyses were conducted using STATA software, version 13.1 (College 151 
Station, Texas).   152 
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RESULTS 153 
Study Selection  154 
Of the 1505 reports initially identified, 1471 remained after removing duplicates. We excluded 1435 rec-155 
ords on the basis of their abstracts and 25 after full text examination (Figure 1). Eleven studies met pre-156 
specified eligibility criteria and were included in the analyses. The agreement among the reviewers was 157 
98.63% for the first screen of abstracts (κ=0.75) and 89.74% for the full-text search (κ=0.71). 158 
 159 
Study Characteristics 160 
Eleven cohorts reported data on 16,805 participants (Table 1). Two cohorts only included men.29,30 Mean 161 
age was 70 years or higher, except for one study.31 The follow-up time ranged from 12 to 152 months 162 
(median follow-up 44.4 months). Eight cohorts excluded participants treated with thyroid hormones or 163 
medications altering thyroid hormone levels, while three excluded the participants taking thyroid hor-164 
mones or thyroid altering medication in sensitivity analysis.32-34  165 
 166 
Description and Quality of Studies  167 
The quality of studies was heterogeneous. Nine cohorts were population-based and two were convenience 168 
samples (Supplement Table 1). All the cohorts used third generation TSH assays, except one using sec-169 
ond generation tests and one that did not report test details.35,36 Four studies had a formal adjudication 170 
committee for dementia diagnosis.29-32 Seven studies provided information on attrition during follow-171 
up.20,29,30,32,33,36,37 Six studies provided information on non-violation of the proportional hazard assumpti-172 
on.29,30,33,34,37,38 All studies reported adjusted data with various confounders, except one study that provided 173 
us unadjusted data.32 174 
 175 
Subclinical Hyperthyroidism and Dementia  176 
Among five cohorts analyzing the association between SHyper and dementia (n=6410, 329 cases of de-177 
mentia, mean follow-up 68.3 months),29-31,37,38 the pooled risk ratio [RR] of dementia was 1.67 (95%CI 178 
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1.04-2.69, I2=0.0%, p for heterogeneity=0.82) among SHyper patients compared with euthyroidism (Fig-179 
ure 2). Sensitivity analyses (Table 2) excluding one study with a convenience-based sample, one study 180 
that followed both patients with and without thyroid hormone replacement, or studies without or not re-181 
ported formal adjudication for dementia, yielded similar results. As the Framingham study only analyzed 182 
the relationship with dementia using TSH tertiles (highest tertile: TSH 1.9-9.9 mU/L) and did not measure 183 
fT4,34 we added this study in a sensitivity analysis and found comparable results. A sensitivity analysis 184 
excluding 475 overlapping patients between two cohorts31,38 yielded similar results; we did not include 185 
these data in the main analysis, as they examined different follow-up duration and were not based on peer-186 
reviewed published results (the investigators sent us these data separately). The relationship between 187 
SHyper and AD was assessed by three studies only (n=3186, 108 AD cases, mean follow-up 75.0 188 
months).30,31,38 The pooled RR for AD was 1.67 (95%CI 0.79-3.51, I2=16.8%, p for heterogeneity=0.30).  189 
 190 
Subclinical Hypothyroidism and Dementia  191 
Among six studies analyzing the relationship between SHypo and dementia (n=7401, 416 cases of demen-192 
tia, mean follow-up 64.6 months),29-32,37,38 the pooled RR for dementia was 1.14 (95%CI 0.84-1.55, 193 
I2=0.0%, p for heterogeneity=0.49) (Figure 2). No individual study showed a statistically significant asso-194 
ciation. Sensitivity analyses (Table 2) excluding a study with a convenience-based sample, studies with 195 
TSH cut-off <4.5mU/l and potentially including individuals in the euthyroid range, two studies that fol-196 
lowed both patients with and without thyroid hormone replacement, studies without or not reported formal 197 
adjudication process for dementia, one study with additional unadjusted data, or 475 overlapping partici-198 
pants between two cohorts31,38 yielded similar results. The addition of the Framingham study34 to the main 199 
analysis yielded similar results. Four studies analyzed the relationship between SHypo and AD (n=3823, 200 
151 AD cases, mean follow-up 69.36 months).30-32,38 The pooled RR for AD was 0.95 (95%CI 0.52-1.71, 201 
I2=0.0%, p for heterogeneity=0.89). 202 
 203 
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Subclinical Hyperthyroidism and MMSE  204 
Among five studies reporting change in MMSE among participants with SHyper (n=7895, mean follow-205 
up 33.6 months),20,31,33,36,37 the pooled mean MMSE decline in cognitive function per year was 0.01 points 206 
difference from baseline (95%CI -0.14-0.15; I2=23.5%, p for heterogeneity=0.27; Supplement Figure 1). 207 
Results remained similar after excluding one study using a convenience-based sample or one study that 208 
followed both patients with and without thyroid hormone replacement (Supplement Table 2). Because 209 
the results of the main analyses between SHyper and dementia did not seem concordant with the results of 210 
the meta-analysis looking at the decrease of MMSE in SHyper participants, we undertook a sensitivity 211 
analysis including the two studies examining the relationship of SHyper and both MMSE and 212 
dementia31,37, which also showed no larger decline of MMSE among SHyper. 213 
 214 
Subclinical Hypothyroidism and MMSE  215 
Among seven studies reporting change in MMSE in SHypo (n=8960; mean follow-up 32.2 months),20,31-216 
33,35-37 pooled mean MMSE per year declines did not significantly differ between SHypo and euthyroid 217 
groups (ES 0.01 points difference from baseline, 95%CI -0.10-0.12, I2=27.6%, p for heterogeneity=0.22; 218 
Supplement Figure 1). Sensitivity analyses (Supplement Table 2) excluding one study with a conven-219 
ience-based sample, studies using TSH cut-offs <4.5mU/l, one study that followed both patients with and 220 
without thyroid hormone replacement, one study that might have subclinical hyperthyroid participants in 221 
the control group,35 or one study using unadjusted data yielded similar results. 222 
 223 
Publication bias 224 
Both graphical inspection and Egger’s tests indicated little evidence of publication bias for all associa-225 
tions, although the number of available studies was small (Supplement Figure 2).39  226 
  227 
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DISCUSSION AND CONCLUSION  228 
In this meta-analysis of 11 prospective cohorts, we found that SHyper, but not SHypo, might be associated 229 
with an elevated risk for dementia, while decline in MMSE over time was minimal for both conditions. 230 
SHyper showed also a similar pattern of higher risk for AD. Results for the association between SHyper 231 
and dementia remained similar when we pooled higher quality studies in sensitivity analysis, such as stud-232 
ies with formal adjudication process for the outcome assessment or population-based studies. 233 
Our results for SHyper and risk for dementia are consistent with a non-systematic literature review sum-234 
marizing results from 13 cross-sectional or case-control, and 10 cohort studies that found supportive evi-235 
dence of an association between SHyper and cognitive impairment or dementia.40 Of these 10 cohort stud-236 
ies, four did not meet the eligibility criteria for our systematic review: one due to missing subgroups of 237 
thyroid dysfunction41, two analyzed only euthyroid participants42,43 and one had a retrospective design14. 238 
Several other individual studies reported an association between SHyper and an elevated risk for dementia 239 
as well14,44,45: a retrospective nested case-control study including 2004 patients with SHyper reported a 240 
hazard ratio for dementia of 1.79 (95%CI 1.28-2.51), and a cross-sectional study found a positive associa-241 
tion between SHyper and dementia in 1276 participants (33 with SHyper) aged >65 years (OR for demen-242 
tia 4.1, 95%CI 1.3-13.1).14,44 Van Osch et al prospectively studied 178 patients with AD and 291 commu-243 
nity-dwelling controls without objective cognitive impairment, and found an adjusted OR for AD of 2.36 244 
(95%CI 1.19-4.67) in participants in the lowest (TSH<1.3mU/l) versus highest TSH tertile 245 
(TSH>2.1mU/l).45 Another population-based prospective cohort of 313 elderly adults with normal TSH 246 
that found that those with a decline of cognitive dysfunction had a mean TSH of 1.78mU/l, while those 247 
without decline had a mean TSH of 2.24mU/l (p=0.001).46  248 
 249 
Our findings might be consistent with the hypothesis that SHyper increases the risk of dementia, although 250 
decline in MMSE over time did not differ between SHyper and euthyroidism. In our meta-analysis, only 251 
two out of 11 studies published results on both dementia and MMSE in SHyper. Analyzing only these two 252 
studies showed no larger decline of MMSE among participants with SHyper. This discrepancy might be 253 
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explained by several factors: the length of follow-up of studies on SCTD and dementia was twice the du-254 
ration of studies on SCTD and MMSE (mean follow-up time 66 vs. 33 months), different population in-255 
vestigated, the modest sensitivity of MMSE as a diagnostic tool (79%)47,48, as well as for detecting mild 256 
cognitive impairment and subtle changes in specific cognitive domains, and the multimodal approach 257 
needed to diagnose dementia.49 Furthermore, different scores were used as gold standard depending on the 258 
type and version of diagnostic criteria (supplement table 1). Factors increasing the plausibility of the 259 
association between SHyper and dementia were that results remained similar when we pooled higher qual-260 
ity studies in sensitivity analysis, such as studies with formal adjudication process for the outcome as-261 
sessment or population-based studies, and that SHyper also showed a pattern of higher risk for AD. How-262 
ever, higher quality studies are needed. 263 
 264 
Several pathways could explain the association of thyroid dysfunction with cognition and dementia. Thy-265 
roid hormone has distinct effects on the cardiovascular system and thyroid dysfunction has been associat-266 
ed with several cardiovascular risk factors, including hypertension, dyslipidemia and atrial fibrillation.4,6 267 
In turn, these cardiovascular risk factors are associated with a higher risk of dementia and Alzheimer’s 268 
Disease.50 Most studies included in our meta-analysis adjusted for cardiovascular risk factors. However, 269 
the number and type of variables that were adjusted for differed for each study. Other explanations for the 270 
association include direct effects of thyroid hormone, such as neurotoxicity and altered gene expression in 271 
pathways relevant for dementia. The exact pathophysiological link between thyroid dysfunction and de-272 
mentia remains unclear and requires more research.  273 
 274 
Recently, two meta analyses on SHypo and cognitive impairment were published, yielding discrepant 275 
results.21,22 The first review included 13 studies and found a significant higher risk for cognitive alteration 276 
(composite endpoint of incidence or prevalence of dementia or difference in MMSE, Wechsler Adult In-277 
telligence scale and Wechsler Memory-Revised score) in SHypo individuals younger than 75 years (OR 278 
1.56; 95%CI 1.07-2.27, p=0.02), and for dementia (OR 1.81; 95%CI 1.43-2.28, p<0.01).21 However, the 279 
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authors pooled different designs (cross sectional, case-control, cohort studies), used a composite endpoint 280 
of clinical events and scales as primary outcome, and found a significant risk for the primary endpoint 281 
only in subclinical hypothyroid individuals younger than 75 years. As results were calculated on the basis 282 
of mean age, without availability of individual patient data, they may have been subject to potential ag-283 
gregation bias (ecological fallacy).51 Contrary to that meta-analysis, all studies in our meta-analysis but 284 
one (included only in a sensitivity analysis) measured fT4 to define SCTD. The second meta-analysis ana-285 
lyzed 15 studies (9 cross-sectional, 6 prospective cohort studies) and found no association between SHypo 286 
and decline in cognitive function among people aged > 60 years (cross-sectional analysis: pooled ES for 287 
MMSE −0.01 points difference from baseline [95%CI −0.09-0.08]; prospective analysis, pooled MMSE 288 
change: 0.03 [95%CI −0.001-0.07] p=0.055, with heterogeneity [I2] of <0.001%),22 which is consistent 289 
with our findings. In comparison to these two meta-analyses, we included only prospective cohorts (n=11) 290 
allowing us to reduce the bias that could arise due to differing study designs. In order to broaden ourTo 291 
make literature search broad enough, we excluded studies examining solely participants with overt thyroid 292 
disease but added no other exclusion criteria. 293 
Two small placebo controlled trials (n=89; n=94) found no evidence that treatment of SHypo with levo-294 
thyroxin was associated with improved cognitive function.18,52 However, these trials had several limita-295 
tions. In the trial by Parle et al,52 recruitment was based on a single thyroid function test, so that euthyroid 296 
participants with transiently elevated TSH may have been included (50% in the placebo group were eu-297 
thyroid at 12 months), which may have underpowered the trial to detect an effect of hormone replace-298 
ment.52 Thyroxin substitution lasted only for 12-months, which may have been too short to affect cogni-299 
tive function. In the trial by Jorde et al,18 one third of participants did not attend follow-up. Because of 300 
numerous exclusion criteria, the study population was unusually healthy, with 57% of the participants 301 
having a TSH value between 3.50 and 4.99mU/l, so that it probably included many euthyroid participants. 302 
The ongoing TRUST (Thyroid Hormone Replacement for Subclinical Hypothyroidism) trial (ClinicalTri-303 
als.gov: NCT01660126) may clarify whether treatment with levothyroxin in SHypo is associated with 304 
better cognitive outcomes over time.53 305 
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There are several strengths of our meta-analysis. By combining the results of 11 prospective cohorts, we 306 
analyzed a total of 432 cases of dementia and 160 cases of AD in more than 15,000 participants. By con-307 
tacting several authors of these studies, we obtained additional data that allowed us to derive more uni-308 
form subgroup and sensitivity analyses. In comparison to the two other meta-analyses,21,22 our results are 309 
less prone to bias due to pooling of heterogeneous study design and quality, because we only included 310 
prospective cohorts. We also conducted a detailed literature search in several electronic databases with as 311 
few limitations as possible in order to retrieve the maximum number of studies available on the topic, and 312 
were able to include a larger number of prospective cohorts than previous meta-analyses.21,22  313 
 314 
Our meta-analysis has also several limitations. Except for two studies30,35, studies only examined Cauca-315 
sians, limiting the generalizability to other populations. All studies were performed in participants with a 316 
mean age >65 years and the time of follow-up was relatively short, ranging between 12 and 70.8 months 317 
(152.4 months in the Framingham Study,34 added in a sensitivity analysis). Except for All but two20,33 318 
studies assessed thyroid function tests only at baseline, which is a limitation of most previously published 319 
large cohort studies on the risks of thyroid dysfunction54,55. Some participants with SCTD at baseline may 320 
have normalized to euthyroidism or progressed to overt thyroid disease over time. Regarding the elderly 321 
participants in the included studies, we cannot exclude a certain degree of some overdiagnosis with of 322 
SHypo due to the physiological rise of TSH towards upper limits during normal ageing56. All these non-323 
differential misclassification of thyroid status might bias the results towards no difference. The limited 324 
sensitivity of MMSE to for detecting subtle changes in specific cognitive domains57, may further limit our 325 
ability to detect verify a possible decline in cognitive function. A meta-analysis of observational studies 326 
requires cautious interpretation of the results and potential biases, and confounding and heterogeneity 327 
must be carefully investigated.58,59 The quality of the incorporated studies was variable. We performed 328 
several sensitivity analyses to address differences between the studies, as recommended,58 although they 329 
should be interpreted with caution given the small number of studies. In study level meta-analysis, inter-330 
pretation of subgroup data should be performed with caution. Because of the small amount of studies, no 331 
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meaningful subgroup analysis could be performed in this study. There are multiple confounders for cogni-332 
tive decline and dementia, the most important is age, others are depression or cardiometabolic risk factors. 333 
All cohorts adjusted for age and several other confounders, but there was heterogeneity in the choice of 334 
confounders, which may lead to residual confounding. Bias in the selection of included studies cannot be 335 
excluded. To limit selection bias, we conducted a detailed literature search in several electronic databases 336 
with broad inclusion. We performed graphical and statistical assessment to assess selective reporting, but 337 
these analyses were not very sensitive considering the small number of studies included.25,28 Although 338 
included cohorts enrolled community-dwelling adults in ambulatory visits, who are therefore less likely to 339 
have an acute disease, some participants with non-thyroidal illness may have been analyzed. Included 340 
studies addressed this problem differently: Two repeatedly measured thyroid values20,33, one assessed and 341 
adjusted for rT3 (reverse triiodothyronine)38, and others adjusted for comorbidities.  We cannot exclude 342 
that some participants had nonthyroidal illness. 343 
What are the potential clinical and research implication of our findings? Our data suggest that SHyper 344 
might represent a potentially treatable risk factor for dementia. Given the relatively high prevalence of 345 
both SCTD and cognitive dysfunction in the aging population, even a modest increase of dementia inci-346 
dence among individuals with SCTD might have public health implications. Data on benefit of SCTD 347 
treatment are scarce, therefore current guidelines do not recommend treatment for most adults with mild 348 
SCTD (serum TSH 0.1-0.45mU/l or 4.5-10.0mU/l).60,61 Large randomized controlled trials are required to 349 
assess the efficacy of treatment in SCTD associated with dementia. For SHypo, the ongoing TRUST (Thy-350 
roid Hormone Replacement for Subclinical Hypothyroidism) trial (ClinicalTrials.gov: NCT01660126) 351 
will clarify this issue.62 352 
 353 
In summary, our systematic review and meta-analysis indicates that SHyper, but not SHypo, might be 354 
associated with a modestly elevated risk of dementia. Neither SHyper nor SHypo were significantly asso-355 
ciated with a faster decline in MMSE over time, as compared to euthyroidism. Available data were lim-356 
ited, and additional large, high-quality prospective cohort studies are needed.  357 
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Table 1. Description of Included Studies for the Effect of Subclinical Thyroid Dysfunction on Dementia/Mini-Mental State Examination 522 
(MMSE) 523 
Study, 
Year of publication Population Women 
Mean age;  
SD 
Follow-
up time Age 
TSH cutoff level 
(mU/l) 
fT4 mea-
sured 
Thyroid 
hormone 
recipients 
excluded? 
 
N % years months 
min-max. 
years SHypo SHyper 
  Rotterdam,31 2000§ 1843 61.9 68.8; 7.5 25.2 55-93 > 4.0 < 0.4 yes yes 
Leiden 85-Plus Study,33 2004 558 66.0 85.0; 0.0 44.4 85 > 4.8 < 0.3 yes in SA 
Rotterdam Scan,38 2006 1077 51.2 72.3†; 7.4 66.0 60-90 > 4.3 < 0.4 yes yes 
Health Ageing,36 2008 1047 51.0 73.6; 6.2 24.0 64-94 > 4.8 < 0.3 yes yes 
Framingham,34 2008‡ 1864 59.0 71.0; 7.0 152.4  ‡ ‡ no in SA 
HAAS,30 2009 665 0.0 78.0 56.4 71-93 > 4.3 < 0.4 yes yes 
Japanese Study,35 2010 229 65.0 80.9; 4.7 12.0 
 
> 4.0 NR yes yes 
Conselice,32 2012§ 660 52.9 73.3; 6.0 45.6 65-91 > 4.5 < 0.45 yes in SA 
HIMS,29 2012 3401 0.0 76.8; 3.5 70.8† 70-89 > 4.0 < 0.4 yes yes 
PROSPER,20 2013 5154 49.4 75.0 38.4 80-82 > 4.5 < 0.45 yes yes 
OCTABAIX,37 2014|| 307 54.6 85.0; 0.0 36.0 85 > 5 < 0.25 yes yes 
Abbreviations: Conselice = Conselice Study of Brain Ageing; Framingham = The Framingham Study; fT4 = free thyroxine; HAAS = Honolulu-Asia Aging Study; 524 
Health Ageing = Health Ageing Study; HIMS = The Health in Men Study; Japanese Study = Cognitive function with subclinical hypothyroidism in elderly people 525 
without dementia: One year follow up; Leiden 85+ = Leiden 85-plus Study; NR = not reported; OCTABAIX = OCTABAIX Study; PROSPER = The PROSPER 526 
Study; Rotterdam Scan = Rotterdam Scan Study; Rotterdam = The Rotterdam Study; SA = sensitivity analysis; SHyper = subclinical hyperthyroidism; SHypo = 527 
subclinical hypothyroidism; TSH = thyrotropin.  528 
† median 529 
‡ The Framingham Study did not use TSH cut-offs for SCTD, but tertiles: tertile 1: 0.1-1.08mU/l for women, 0.10-0.90mU/l for men; tertile 2: 1.10-2.03mU/l for 530 
women, 0.99-1.80mU/l for men; tertile 3: 2.10-9.90mU/l for women, 1.09-9.90mU/l for men. Therefore, this study could not be included in the meta-analysis 531 
but was added to a sensitivity analysis.  532 
§ Due to additional unpublished data provided by the authors, the studies could be incorporated in the meta-analysis on SCTD and MMSE; unadjusted data. 533 
|| Due to additional unpublished data provided by the authors, the study could be incorporated in the meta-analysis on SCTD and dementia. 534 
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Table 2: Sensitivity Analyses on the Association between Subclinical Thyroid Dysfunction (SCTD) 535 
and Dementia  536 
 
RR† 95% CI p for hetero-geneity 
N of 
studies 
Subclinical Hyperthyroidism and Dementia 
    Main analysis29-31,37,38 1.67 1.04, 2.69 0.82 5 
Exclusion of one study using a convenience-based sample30,31,37,38 1.73 1.07, 2.80 0.82 4 
Exclusion of one study enrolling patients with and without thyroid 
hormone replacement29,31,37,38  1.73 0.96, 3.11 0.68 4 
Exclusion of studies without formal adjudication30,31  1.86 0.96, 3.62 0.46 2 
Exclusion of overlapping 475 participants from 2 studies 29-31,37,38‡ 1.60 0.92, 2.78 0.82 5 
Main analysis adding the Framingham Study29-31,34,37,38 § 1.46 1.08, 1.97 0.84 6 
 
Subclinical Hypothyroidism and Dementia 
    Main analysis29-32,37,38 1.14 0.84, 1.55 0.49 6 
Exclusion of one study using a convenience-based population30-
32,37,38 1.31 0.91, 1.89 0.65 5 
Exclusion of studies with TSH cut-off <4.5mU/l32,37 1.36 0.91, 2.05 0.59 2 
Exclusion of two studies enrolling patients with and without thy-
roid hormone replacement29,31,37,38 1.14 0.69, 1.90 0.29 4 
Exclusion of studies without formal adjudication process30-32 1.14 0.73, 1.78 0.57 3 
Exclusion of one study with unadjusted data29-31,37,38 1.06 0.71, 1.60 0.39 5 
Exclusion of overlapping 475 participants from 2 studies29-32,37,38 ‡ 1.10 0.80, 1.50 0.66 6 
Main analysis adding the Framingham Study 29-32,34,37,38§ 1.18 0.91, 1.52 0.60 7 
Abbreviations: CI = confidence interval; N = number; RR = risk ratio; SCTD = subclinical thyroid dysfunction; TSH = 537 
thyrotropin. 538 
† RR>1 indicates higher risk of an event in SCTD than in euthyroidism. A positive mean difference indicates larger 539 
decrease in cognitive function in SCTD than in euthyroidism.  540 
‡ Performed on data additionally provided by the author; we did not include these data in the main analysis, as they 541 
examined different follow-up duration and were not based on peer-reviewed published results (the investigators sent us 542 
these data separately) 543 
§ As the Framingham Study did not use TSH cut-off for SCTD, we compared lowest versus highest tertiles (lowest 544 
tertile: 0.10-1.08 for women, 0.10-0.90 for men; highest tertile 2.10-9.90 for women, 1.90-9.90 for men).34  545 
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Figure 1: Study Evaluation for Inclusion in the Meta-Analysis, adapted from PRISMA Statement 546 
Flow Diagram 547 
 548 
 549 
(36, 43) 550 
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 572 
* Until November 11, 2014 for MEDLINE and November 14, 2014 for EMBASE.  573 
† From key articles in the field and contact with authors.  574 
  575 
Records identified 
through database 
searching* 
(n=1505) 
Additional record 
identified through 
other sources† 
(n=0)  
1471 records screened  
 
11 studies included in qualitative 
synthesis  
1435 records excluded based on title and ab-
stract (not a prospective study on the associa-
tion between thyroid hormones and cognition) 
10 studies included in quantitative 
synthesis (meta-analysis)  
25 of full-text articles excluded:  
No full text available because review, 
meeting abstract, poster or editorial (n=5)  
No thyroid function test (n=8) 
Reported the same study already selected 
without additional data to extract (n=1) 
No prospective study (n=11) 
 
36 full-text articles assessed for 
eligibility  
Records after duplicates removed 
(n=1471) 
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Figure 2: Association between Subclinical Thyroid Dysfunction and Dementia 
SHyper and Dementia 
 
SHypo and Dementia 
 
Legend, Figure 2: RR>1 indicates higher risk of an event in SCTD than in euthyroidism. Abbreviations: 95%CI = 95% 576 
confidence interval; Euthyroid = euthyroidism; n = number of patients with dementia per group; N = total number of 577 
patients per group; SHyper = subclinical hyperthyroidism; SHypo = subclinical hypothyroidism578 
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Supplement Table 1: Quality Assessment of Included Studies 579 
Study Population, setting 
Assessment of 
dementia or Alz-
heimer's Disease 
Formal 
adjudica-
tion for 
dementia or 
Alzheimer’s 
Disease 
Blinding of 
study inves-
tigators 
regarding 
TSH 
Blinding 
of pa-
tients 
regarding 
TSH 
Loss of FUP 
(reasons for 
incomplete-
ness) 
 
TSH 
assess
sess-
ment 
TSH 
assay  Adjustment for potential confounders 
Rotterdam,31 
2000 
population-
based, ambu-
latory / sub-
jects in insti-
tutions 
D: DSM-III-R (3-
step-screening: 1. 
MMSE (<26), 
GMSS (<0); 2. 
CAMDEX; 3. 
Neurologist, Neu-
ropsychologist, 
Brain Image); AD: 
NINCDS-ADRDA 
yes NR NR NR 
 
 
 
 
BL 3
rd 
 
Age, sex, atrial fibrillation, education 
(years), cigarette smoking (never, former, 
current), depressive symptoms, APOE 
Leiden 85-
Plus Study, 33 
2004 
population-
based, ambu-
latory 
not assessed dementia  not assessed NR NR 
279 (death 
[209], refusal 
[70]) 
 
BL + 
3 year 
FUP 
3rd  
 
**, Sex, self-reported educational level 
(<6 vs > 6 years of education), albumin, 
CRP, MMSE at baseline, subjective 
health, type 2 diabetes, myocardial infarc-
tion, stroke, COPD, arthritis, Parkinson 
disease 
Rotterdam 
Scan,38 2006 
population-
based, ambu-
latory / sub-
jects in insti-
tutions 
D: DSM-III-R 
(MR for all study 
subjects, then three 
step protocol for 
screening: 1. 
Screening MMSE 
(<26) and GMSS 
(>0); 2. CAMDEX; 
3. Neuropsycholo-
gical testing);AD: 
NINCDS-ADRDA 
NR NR NR NR 
 
 
 
 
 
 
 
 
 BL 
3rd  
Age, sex, educational level, depressive 
symptoms, cigarette smoking, cardiac 
medication, beta-blockers, systemic 
corticosteroid use, atrial fibrillation, 
diabetes mellitus, BMI; total cholesterol 
and HDL levels, creatinine, homocysteine 
level, T3/rT3, TPO-AB 
Health Age-
ing,36 2008 
population-
based, ambu-
latory 
not assessed dementia  not assessed yes NR 148 
 
BL 2nd 
 
Age, sex, education, mood, baseline 
MMSE, high blood pressure, smoking, 
history of diabetes mellitus, heart attack, 
stroke, study site 
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Study Population 
Assessment of 
dementia or Alz-
heimer's Disease 
Formal 
adjudica-
tion for 
dementia or 
Alzheimer’s 
Disease 
Blinding of 
study inves-
tigators 
regarding 
TSH 
Blinding 
of pa-
tients 
regarding 
TSH 
Loss of FUP 
(reasons for 
incomplete-
ness) 
 
TSH 
assess
sess-
ment 
TSH 
assay Adjustment for potential confounders 
Framing-
ham,34 2008 
population-
based, ambu-
latory 
D: DSM-IV and 
Clinical Dementia 
Rating ≥1 and 
symptoms of de-
mentia ≥ 6 months 
(Multi step proto-
col:1.Neuropsycho-
logical Testing, 
MMSE; 2. Neuro-
logical- and neuro-
psychological 
examinations); AD: 
NINCDS-ADRDA 
yes NR NR 295 (reason unclear) 
2 
years 
before 
BL 
3rd 
Age, APOE, education level (dichoto-
mized: high school completion yes/no), 
plasma homocysteine, current smoking, 
body-mass index, prevalent stroke, atrial 
fibrillation 
HAAS,30 
2009 
population-
based, ambu-
latory 
D: DSM-III-R 
(Multi step proto-
col: 1. CASI; 2. 
CERAD; 3. Neuro-
logic Exam and 
Interview. In case 
of Dementia: neu-
roimaging and 
blood test); AD: 
NINCDS-ADRDA; 
CERAD 
yes NR NR 
335 (dementia 
at BL [131], 
death or re-
fusal [204]) 
BL 3rd 
Age, age at death (autopsy-study), educa-
tional level, depressive symptoms, diabetes 
mellitus, smoking status, systolic and dias-
tolic blood pressure, use of thyroid medica-
tion, thyroid-altering drugs (incl. beta-
blocking agents and anti-arrhythmics), BMI, 
biochemical markers (albumin, total and 
HDL cholesterol, APOE). 
Japanese 
Study,35 2010 
population-
based, ambu-
latory 
not assessed dementia  not assessed NR NR NR BL NR 
Sex, age, BMI, physical status, diabetes 
mellitus, cardiovascular disease, hyper-
tension, dyslipidemia, points of BL cog-
nitive function, arterial stiffness. 
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Study Population 
Assessment of 
dementia or Alz-
heimer's Disease 
Formal 
adjudica-
tion for 
dementia or 
Alzheimer’s 
Disease 
Blinding of 
study inves-
tigators 
regarding 
TSH 
Blinding 
of pa-
tients 
regarding 
TSH 
Loss of FUP 
(reasons for 
incomplete-
ness) 
 
TSH 
assess
sess-
ment 
TSH 
assay Adjustment for potential confounders 
Conselice,32 
2012 
population-
based, ambu-
latory 
D: DSM-IV (Multi 
step screening: 1. 
Interview, IADL, 
GDS, MMSE (<24; 
>9), neurological 
examination, blood 
test; 
2.Neuropsychologi
cal testing with 
Mental Deteriora-
tion Battery, Prose 
Memory Test); AD: 
NINCDS-ADRDA 
yes no NR 
Exclusion at 
BL: dementia 
[60], MCI 
[71], unclassi-
fiable cogni-
tive status 
[22],at BL or 
FUP ; missing 
laboratory data 
[32], missing 
information 
about cognitive 
status at FUP 
[82], due to 
death [82], 
refusal [52] or 
failure to be 
traced 
BL 3rd * 
HIMS,29 
2012 
convenience-
based, ambu-
latory 
D: ICD-9/10 NR NR NR 
2848 (exclu-
sion due to: 
history of 
thyroid disease 
[2139], thyroid 
drugs [71], 
missing data 
[82], hyperthy-
roidism [14], 
prevalent 
dementia [12], 
with SMMSE 
< 24 [521], fT4 
< 9 pmol/l [1], 
fT4 > 25pmol/l 
[8]) 
BL 3rd 
Age, BMI, smoking-status, education, 
SMMSE, social support, medical comor-
bidities, sensorial impairment 
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Study Population 
Assessment of 
dementia or Alz-
heimer's Disease 
Formal 
adjudica-
tion for 
dementia or 
Alzheimer’s 
Disease 
Blinding of 
study inves-
tigators 
regarding 
TSH 
Blinding 
of pa-
tients 
regarding 
TSH 
Loss of FUP 
(reasons for 
incomplete-
ness) 
 
TSH 
assess
sess-
ment 
TSH 
assay Adjustment for potential confounders 
PROSPER,20 
2013 
convenience-
based, ambu-
latory 
not assessed dementia  not assessed NR NR 
650 (exclusion 
at BL: antithy-
roid drugs [6], 
levothyrox-
ine[159], 
amiodarone 
[20], high fT4 
and high TSH 
[7], low fT4 
and low TSH 
[1], overt 
thyroid disease 
[146], missing 
fT4 [303], 
missing TSH 
[8]) 
BL + 
at 6 
Month 
3rd Sex, age, education, country, Apo E genotype 
OCTA-
BAIX,37 
2014 
population-
based, ambu-
latory 
NR 
(Assessments: BI, 
BADL, LI; MMSE 
<23/35pts; Mini 
Nutritional As-
sessment, Gait 
Rating Scale, QoL-
VAS, CS) 
NR NR NR 
102 (death 
during FUP 
[51], from the 
256 surviving 
patients only 
205 with geri-
atric assess-
ment, reason 
unclear) 
BL 3rd 
**, Sex, education, marital status, cardio-
vascular risk factors such as treatment for 
high blood pressure above 140/90, diabe-
tes mellitus, dyslipidemia, heart failure, 
medication, prevalence for stroke or 
dementia, number of drugs prescribed 
Abbreviations: AD = Alzheimer’s disease; APOE = Apolipoprotein-E Ɛ4 allele status; BADL = Basic Activities of Daily Living; BI = Barthel Index; BL = Baseline; BMI = 583 
Body mass index; CAMDEX = Cambridge examination for mental disorders of the elderly ; CASI = Cognitive Abilities Screening Instrument; CERAD = Consortium to Es-584 
tablish a Registry for Alzheimer Disease battery; Conselice = Conselice Study of Brain Ageing; COPD = Chronic obstructive pulmonary disease; CRP = C-reactive protein; 585 
CS = Charlson Score; D = dementia; DSM = Diagnostic and Statistical Manual of Mental Disorders; Framingham = The Framingham Study; fT4 = Free thyroxine; FUP = 586 
Follow-up; GDS = Geriatric Depression Scale; GMSS = Geriatric Mental State Schedule ; HAAS = Honolulu-Asia Aging Study; HDL = High-density lipoproteins; Health 587 
Ageing = Health Ageing Study; HIMS = The Health in Men Study; IADL = Instrumental Activities of Daily Living; ICD = International Statistical Classification of Diseases 588 
and Related Health Problems; Japanese Study = Cognitive function with subclinical hypothyroidism in elderly people without dementia: One year follow up; Leiden 85+ = 589 
Leiden 85-Plus Study; LI = Lawton Index; MCI: Mild cognitive impairment; MMSE = Mini Mental State Exam; NINCDS-ADRDA = National Institute of Neurological and 590 
Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association; NR = Not reported; OCTABIX = OCTABAIX Study; PROSPER = The 591 
PROSPER Study; pts = points; QoL-VAS = Quality of Life Test Visual Analogue Scale; Rotterdam Scan = Rotterdam Scan Study; Rotterdam = The Rotterdam Study; SA = 592 
Field Code Changed
Field Code Changed
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Sensitivity analysis; SHyper = Subclinical hyperthyroidism; SHypo = Subclinical hypothyroidism; SMMSE = Standardized mini mental state exam; TPO-AB = Thyroid pe-593 
roxidase antibodies; TSH = thyrotropin. 594 
 595 
* unadjusted additional data has been used for this meta-analysis. The original study adjusted for age, sex, education, serum cholesterol, Geriatric Depression Scale Score, 596 
BMI, hypertension, diabetes mellitus, history of cardiovascular disease, plasma total homocysteine. 597 
** No adjustment for age because of same aged cohort. 598 
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Supplement Table 2: Sensitivity Analyses on the Association between Subclinical Thyroid Dysfunc-600 
tion and Annualized Mean Change in Mini-Mental State Examination (MMSE) 601 
 
ES 95% CI p for hetero-geneity 
N. of 
studies 
Subclinical Hyperthyroidism and MMSE  
    Main analysis20,31,33,36,37  0.01  -0.14, 0.15 0.27 5 
Exclusion of one study using a convenience-based 
population31,33,36,37  0.06 -0.36, 0.49 0.20 4 
Exclusion of one study enrolling patients with and without 
thyroid hormone replacement20,31,33,37 -0.01 -0.11, 0.09 0.68 4 
Studies indicating results for both MMSE and dementia31,37 -0.09 -0.26, 0.08 0.80 2 
 
Subclinical Hypothyroidism and MMSE 
    Main analysis20,31-33,35-37  0.01 -0.10, 0.12 0.22 7 
Exclusion of one study using a convenience-based population31-
33,35-37  0.06 -0.06, 0.18 0.48 6 
Exclusion of studies with TSH cut-off <4.5mU/l20,32,33,36,37  0.07 -0.13, 0.28 0.09 5 
Exclusion of one study Exclusion of one study enrolling pa-
tients with and without thyroid hormone replacement20,31-33,35,37 -0.01 -0.12, 0.11 0.22 6 
Exclusion of one study with unadjusted data20,31,33,35-37 -0.06 -0.13, 0.01 0.70 6 
Studies indicating results for both MMSE and dementia31,32,37  0.06 -0.14, 0.26 0.18 3 
Exclusion of the Japanese Study20,31-33,36,37†  0.01 -0.11, 0.13 0.16 6 
Abbreviations: MD = mean difference in change from baseline for mini mental state exam score. MD >0 indicates 602 
higher decline of MMSE in SCTD than in euthyroidism.  603 
Abbreviations: CI = confidence interval; ES = effect size, defined as annualized mean change in MMSE; MMSE = 604 
Mini-Mental State Examination; N = number; SCTD = subclinical thyroid dysfunction; TSH = thyrotropin. 605 
† This study35 was excluded in the sensitivity analysis, because it might have included subclinical hyperthyroid par-606 
ticipants in the control group. 607 
608 
31 
 
 
 
Supplement Figure 1: Association between Subclinical Thyroid Dysfunction and Annualized Mean 609 
Change in Mini-Mental State Examination (MMSE) 610 
SHyper and MMSE 
 
SHypo and MMSE 
  
Legend, Supplement Figure 1: MD = mean difference in change from baseline for MMSE score. MD>0 indicates 611 
higher decline of MMSE in SCTD than in euthyroidism. Abbreviations: 95%CI = 95% confidence interval; MD = 612 
annualized differences in mean change from baseline in MMSE; Euthyroid = euthyroidism; MMSE = Mini-Mental 613 
State Examination; n = number of patients with dementia per group; N = total number of patients per group; SHyper 614 
= subclinical hyperthyroidism; SHypo = subclinical hypothyroidism. 615 
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Supplement Figure 2: Funnel Plots and Egger’s Tests 
SHyper and Dementia SHypo and Dementia 
  
SHyper and MMSE SHypo and MMSE 
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